Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.68 |
| ▸ | GSK3B | P49841 | 1/20 | 0.68 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 5/20 | 0.59 |
| ▸ | CA2 | P00918 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540405 | 0.86 | SMN1; SMN2 (0.71) | MAPTNPC1RAB9AALDH1A1PARP10 | |
| SCHEMBL153386 | 0.84 | ALDH1A1 (0.76) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL16552644 | 0.84 | MMP1 (0.76) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28029377 | 0.84 | HDAC8 (0.65) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2633872 | 0.83 | MAPT (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL459470 | 0.83 | KMT2A (0.70) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1267569 | 0.83 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4082864 | 0.81 | PDE4B (0.86) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5806919 | 0.81 | HDAC3 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL182867 | 0.81 | HDAC3 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116606312-B | Near infrared two-region photosensitizer based on aza-boron dipyrrole, preparation method and application | 西北工业大学 | 2025-05-20 | — | — | CN | claimed |
| CN-118879135-B | Strong-adhesion and high-weather-resistance water-based fluorocarbon paint for GRPU base materials and preparation method thereof | 上海颜钛实业有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-117442600-B | Atomized essence additive, atomized essence and aerosol generating device | 深圳昱朋科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117442600-A | Atomized essence additive, atomized essence and aerosol generating device | 深圳昱朋科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-116999417-A | Liquid preparation containing paeonol and apocynin | AKL研究发展有限公司 | 2023-11-07 | — | — | CN | claimed |
| CN-114751870-B | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxybenzoate and derivative thereof, and synthetic method and application thereof | 贵州医科大学 | 2023-10-20 | — | — | CN | claimed |
| US-20230330017-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | AKL RES & DEVELOPMENT LTD (GB) | 2023-10-19 | — | — | US | claimed |
| CN-116813501-A | Chalcone fluorescent probe, preparation method thereof and detection method for H 2 Application in S | 广东省科学院化工研究所 | 2023-09-29 | — | — | CN | claimed |
| CN-116606312-A | Near infrared two-region photosensitizer based on aza-boron dipyrrole, preparation method and application | 西北工业大学 | 2023-08-18 | — | — | CN | claimed |
| CN-113999218-B | Flavonol compound, preparation method and application thereof in detection of biological mercaptan | 德州学院 | 2023-06-09 | — | — | CN | claimed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | claimed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | claimed |
| EP-1581207-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1746888-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2007-01-31 | — | — | EP | claimed |
| JP-2006510736-A | — | — | 2006-03-30 | — | — | JP | claimed |
| WO-2005112640-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2005-12-01 | — | — | WO | claimed |
| EP-1581207-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | claimed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | claimed |
| WO-2004005280-A1 | NOVEL QUINOLINIC COMPOUNDS SHOWING A FEATURE OF EXCITED-STATE INTRAMOLECULAR PROTON TRANSFER (ESIPT) | DONGWOO FINE-CHEM CO., LTD. (KR) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | HDAC3 896/4885HDAC4 858/4885HDAC1 1096/4885 |
| US-20230330017-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | LPL, PNLIP, LPO | HDAC3 3155/4885HDAC4 2719/4885HDAC1 1237/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | HDAC3 896/4885HDAC4 858/4885HDAC1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.